Evidence map›Paper›PMID 38559034›Full record

ArticlebioRxiv : the preprint server for biology2024

Synthetic dosage-compensating miRNA circuits allow precision gene therapy for Rett syndrome.

Michael J Flynn, Acacia M H Mayfield, Rongrong Du, Viviana Gradinaru, Michael B Elowitz

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Michael J FlynnDivision of Engineering and Applied Sciences, California Institute of Technology, Pasadena, CA 91125.ORCID 0009-0003-1186-957X
Acacia M H MayfieldDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.ORCID 0000-0001-7308-6480
Rongrong DuDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.ORCID 0009-0003-4942-3020
Viviana GradinaruDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.ORCID 0000-0001-5868-348X
Michael B ElowitzDivision of Engineering and Applied Sciences, California Institute of Technology, Pasadena, CA 91125.ORCID 0000-0002-1221-0967
California Institute of Technology · US

Funding

Cell targeting with synthetic sense-and-respond protease circuitsR01EB030015 · NIBIB · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI ELOWITZ, MICHAEL B · 2020 to 2023
$2.3M
Broadening access with an Armamentarium Vector Core Powered by Inclusive Research Experiences - SUPPLEMENTU24MH131054 · NIMH · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI GRADINARU, VIVIANA, SHAY, TIMOTHY FRANCIS · 2022 to 2024
$1.9M
NIBIB NIH HHS R01 EB030015NIMH NIH HHS U24 MH131054
6 · The paper itself

Abstract

A longstanding challenge in gene therapy is expressing a dosage-sensitive gene within a tight therapeutic window. For example, loss of

Identifiers

PMID38559034
PMCPMC10980028
OpenAlexW4392861031

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.